Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 22:9:135.
doi: 10.1186/1471-2334-9-135.

Serogroup C meningococci in Italy in the era of conjugate menC vaccination

Affiliations

Serogroup C meningococci in Italy in the era of conjugate menC vaccination

Paola Stefanelli et al. BMC Infect Dis. .

Abstract

Background: To assess changes in the pattern of Invasive Meningococcal Disease (IMD) in Italy after the introduction of conjugate menC vaccine in the National Vaccine Plan 2005-2007 and to provide information for developing timely and appropriate public health interventions, analyses of microbiological features of isolates and clinical characteristics of patients have been carried out. In Italy, the number of serogroup C meningococci fell progressively following the introduction of the MenC conjugate vaccine, recommended by the Italian Ministry of Health but implemented according to different regional strategies.

Methods: IMD cases from January 2005 through July 2008 reported to the National Meningococcal Surveillance System were considered for this study. Serogrouping and sero/subtyping were performed on 179 serogroup C strains received at the National Reference Laboratory of the Istituto Superiore di Sanità. Antibiotic susceptibility testing was possible for 157 isolates. MLST (Multilocus sequence typing), porA VRs (Variable Region) typing, PFGE (Pulsed Field Gel Electrophoresis), VNTR (Variable Number Tandem Repeats) analyses were performed on all C:2a and C:2b meningococci (n = 147), following standard procedures.

Results: In 2005 and 2008, IMD showed an incidence of 0.5 and 0.3 per 100,000 inhabitants, respectively. While the incidence due to serogroup B remained stable, IMD incidence due to serogroup C has decreased since 2006. In particular, the decrease was significant among infants. C:2a and C:2b were the main serotypes, all C:2a strains belonged to ST-11 clonal complex and all C:2b to ST-8/A4. Clinical manifestations and outcome of infections underlined more severe disease caused by C:2a isolates. Two clusters due to C:2a/ST-11 meningococci were reported in the North of Italy in December 2007 and July 2008, respectively, with a high rate of septicaemia and fatal outcome.

Conclusion: Public health surveillance of serogroup C invasive meningococcal disease and microbiological/molecular characterization of the isolates requires particular attention, since the hyper-invasive ST-11 predominantly affected adolescents and young adults for whom meningococcal vaccination was not recommended in the 2005-2007 National Vaccine Plan.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Annual incidence of serogroup B and C invasive meningococcal disease in Italy, 1995–2008 (cases per 100,000 inhabitants).
Figure 2
Figure 2
Dendrogram of similarity obtained with Dice coefficients and arithmetic averages (UPGMA) clustering method using BioNumerics software (version 3.5) showing the relatedness of representative Pulsed Field Gel Electrophoresis patterns of Nhe I-digested DNAs of 147 C:2a and C:2b meningococci. Patterns that were <85% similar (see scale in the upper left corner) were considered different.
Figure 3
Figure 3
VNTR patterns among meningococcal C:2a isolates recovered from locally related isolates (Veneto and Lombardy cluster strains) in Italy. On the right, phenotypes and PFGE patterns are reported.

References

    1. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31:101–107. doi: 10.1111/j.1574-6976.2006.00053.x. - DOI - PubMed
    1. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359:1829–1831. doi: 10.1016/S0140-6736(02)08679-8. - DOI - PubMed
    1. Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C, Vazquez JA. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill. 2004;9:11–15. - PubMed
    1. Alonso JM, Gilmet G, Rouzic EM, Nassif X, Plotkin SA, Ramsay M. Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9–11 March 2005. Vaccine. 2007;25:4125–4129. doi: 10.1016/j.vaccine.2007.03.001. - DOI - PubMed
    1. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717–722. - PubMed

Publication types

MeSH terms